doxorubicin hydrochloride has been researched along with erlotinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anil Kumar, NV; Rodrigues, FC; Thakur, G | 1 |
| Cai, Z; Ghaleb, H; Huang, W; Jiang, Y; Liu, Y; Qian, H; Qiu, Q; Shi, W; Yin, Z; Zhang, P; Zhou, J; Zou, F | 1 |
1 review(s) available for doxorubicin hydrochloride and erlotinib
| Article | Year |
|---|---|
Developments in the anticancer activity of structurally modified curcumin: An up-to-date review.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Curcumin; Humans; Molecular Structure | 2019 |
1 other study(ies) available for doxorubicin hydrochloride and erlotinib
| Article | Year |
|---|---|
Exploration of novel phthalazinone derivatives as potential efflux transporter inhibitors for reversing multidrug resistance and improving the oral absorption of paclitaxel.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Paclitaxel | 2022 |